Howard Welgus plans $99,980 Arcutis share sale

Arcutis Biotherapeutics submitted a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated 06/15/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics submitted a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated 06/15/2026. The filing lists underlying grants described as stock option exercises (counts: 822, 1,019, 2,255) tied to earlier grant dates and shows two recent sales by Howard Welgus of 10,000 and 7,144 shares during April–May 2026.

Insights

Securities Compliance Analyst

Form 144 notifies the market of proposed insider sales and lists recent dispositions.

The filing identifies 4,096 shares of Common Stock to be sold pursuant to notice dated 06/15/2026. It also records underlying option exercises dated 11/20/2019, 05/31/2023, and 06/14/2024 with counts of 822, 1,019, and 2,255.

Two recent dispositions by Howard Welgus are recorded: 10,000 shares on 04/01/2026 (proceeds $238,800) and 7,144 shares on 05/01/2026 (proceeds $164,219.71). Timing and execution details beyond the notice are not provided in the excerpt.

Key Figures

Shares listed for sale: 4,096 shares Underlying option exercises (counts): 822; 1,019; 2,255 shares Recent disposition by Howard Welgus: 10,000 shares +1 more

4 metrics

Shares listed for sale 4,096 shares Form 144 notice dated 06/15/2026

Underlying option exercises (counts) 822; 1,019; 2,255 shares Grant/exercise dates 11/20/2019; 05/31/2023; 06/14/2024

Recent disposition by Howard Welgus 10,000 shares Sale on 04/01/2026 for $238,800

Recent disposition by Howard Welgus 7,144 shares Sale on 05/01/2026 for $164,219.71

Key Terms

Form 144, stock option exercise, proceeds

3 terms

Form 144 regulatory

"Filer Information ... 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

stock option exercise financial

"Stock Option Exercise | Arcutis Biotherapeutics"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

proceeds financial

"04/01/2026 | 10000 | 238800"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:11 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4096	99980.49	125083374	06/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/20/2019	Stock Option Exercise	Arcutis Biotherapeutics			822	06/15/2026	Cash
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1019	06/15/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			2255	06/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	04/01/2026	10000	238800
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	05/01/2026	7144	164219.71

144: Remarks and Signature

Remarks
Date of Notice	06/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)